BioForce director sells 26.7M shares of stock

Q: What did the BFNH director report selling in this Form 4?

The director reported selling 26,700,000 shares of BIOFORCE NANOSCIENCES common stock on April 22, 2026 at a price of $0.015 per share in an open-market or private transaction.

Q: What stock gifts did the BFNH director report on April 20, 2026?

On April 20, 2026, the director reported two bona fide gifts of BIOFORCE NANOSCIENCES common stock totaling 24,712,000 shares: 20,580,000 shares at $0.007 per share and 4,132,000 shares at $0.001 per share.

Q: What type of security is involved in the BFNH Form 4 transactions?

All reported transactions involve Common Stock; Par Value $0.001 of BIOFORCE NANOSCIENCES HOLDINGS, INC.

Q: What roles does the reporting person hold at BFNH?

The reporting person, Merle Ferguson, is identified in the filing as a director of BIOFORCE NANOSCIENCES HOLDINGS, INC. and is not marked as an officer or ten percent owner in the relationship fields.

A BIOFORCE NANOSCIENCES director reported a large share sale and substantial stock gifts without a Rule 10b5-1 trading plan.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) director Merle Ferguson reported multiple transactions in the company’s common stock. On April 22, 2026, Ferguson sold 26,700,000 shares of common stock at $0.015 per share in a sale described as an open-market or private transaction.

On April 20, 2026, Ferguson reported two bona fide gifts of common stock totaling 24,712,000 shares (20,580,000 shares at $0.007 per share and 4,132,000 shares at $0.001 per share). No post-transaction share balance is reported in this filing, and no Rule 10b5-1 trading plan is indicated.

Insider Trade Summary

Net Seller: 26,700,000 shares

Net Sell 3 txns

Insider Ferguson Merle

Role Director

Sold 26,700,000 shs ($401K)

Type	Security	Shares	Price	Value
Sale	Common Stock; Par Value $0.001	26,700,000	$0.015	$401K
Gift	Common Stock; Par Value $0.001	20,580,000	$0.007	$144K
Gift	Common Stock; Par Value $0.001	4,132,000	$0.001	$4K

Holdings After Transaction: Common Stock; Par Value $0.001 — 0 shares (Direct)

Key Figures

Shares sold: 26,700,000 shares Sale price per share: $0.015 per share Gifted shares (first gift): 20,580,000 shares +4 more

7 metrics

Shares sold 26,700,000 shares Common stock sale reported for April 22, 2026

Sale price per share $0.015 per share Price for 26,700,000-share sale on April 22, 2026

Gifted shares (first gift) 20,580,000 shares Bona fide gift of common stock on April 20, 2026 at $0.007 per share

Gift price per share (first gift) $0.007 per share Per-share value associated with 20,580,000-share gift on April 20, 2026

Gifted shares (second gift) 4,132,000 shares Bona fide gift of common stock on April 20, 2026 at $0.001 per share

Gift price per share (second gift) $0.001 per share Per-share value associated with 4,132,000-share gift on April 20, 2026

Total gifted shares 24,712,000 shares Sum of both bona fide gifts of common stock on April 20, 2026

Key Terms

bona fide gift, Common Stock; Par Value $0.001, Rule 10b5-1, open market or private transaction

4 terms

bona fide gift financial

"The transaction code G is described as a bona fide gift of common stock"

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

Common Stock; Par Value $0.001 financial

"Each transaction involves Common Stock; Par Value $0.001 of the issuer"

Rule 10b5-1 regulatory

"The form-level checkbox indicates whether trades are under a Rule 10b5-1 plan"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open market or private transaction financial

"The sale transaction is described as a sale in open market or private transaction"

FAQ

What did the BFNH director report selling in this Form 4?

The director reported selling 26,700,000 shares of BIOFORCE NANOSCIENCES common stock on April 22, 2026 at a price of $0.015 per share in an open-market or private transaction.

What stock gifts did the BFNH director report on April 20, 2026?

On April 20, 2026, the director reported two bona fide gifts of BIOFORCE NANOSCIENCES common stock totaling 24,712,000 shares: 20,580,000 shares at $0.007 per share and 4,132,000 shares at $0.001 per share.

Were the BFNH transactions made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as being under a plan, indicating no Rule 10b5-1 trading plan is reported for these transactions.

What type of security is involved in the BFNH Form 4 transactions?

All reported transactions involve Common Stock; Par Value $0.001 of BIOFORCE NANOSCIENCES HOLDINGS, INC.

Does the BFNH Form 4 show how many shares the director owns after these transactions?

No. Each transaction row lists the post-transaction holdings field as null, so this Form 4 does not state the director’s remaining share balance after the reported sale and gifts.

What roles does the reporting person hold at BFNH?

The reporting person, Merle Ferguson, is identified in the filing as a director of BIOFORCE NANOSCIENCES HOLDINGS, INC. and is not marked as an officer or ten percent owner in the relationship fields.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/02/2026 - 04:10 PM Accepted by SEC EDGAR 09/02/2026 - 04:09 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ferguson Merle

(Last)

(First)

(Middle)

150 BARBARA LANE

(Street)

ENCINITAS

CALIFORNIA

92024

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOFORCE NANOSCIENCES HOLDINGS, INC. [ BFNH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock; Par Value $0.001	04/20/2026		G		20,580,000	A	$0.007	22,568,000	D
Common Stock; Par Value $0.001	04/20/2026		G		4,132,000	A	$0.001	26,700,000	D
Common Stock; Par Value $0.001	04/22/2026		S		26,700,000	D	$0.015	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ Merle Ferguson	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR